Saskia H.
- Country
- The Netherlands
- Department
- Medical Rehabilitation
Research Overview
- Phase 2 Open‑Label Extension of ENTR‑601‑45 (with ENTR‑601‑44) in Exon‑Skipping‑Amenable Duchenne Muscular Dystrophy: Safety, Tolerability, PK and Efficacy
- Dose-Escalation and Comparative Study of Eteplirsen in Duchenne Muscular Dystrophy Patients with Exon 51 Skipping Mutations
- Long-term Safety and Efficacy Evaluation of Vamorolone in Duchenne Muscular Dystrophy Patients Post-Completion of Prior Vamorolone Studies
Data & Insights
Has run more than one trial at 13 of 27 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the treatment of Duchenne Muscular Dystrophy (DMD), with extensive experience in evaluating novel therapeutic approaches for this progressive muscle disorder.
- Motor Function Assessment
- Long-term Treatment Evaluation
- Progressive Muscle Disease Management
Their research encompasses monitoring disease progression and therapeutic responses in DMD patients.
Therapeutic Development
The investigator focuses on advancing innovative treatment modalities for muscular dystrophy, including the evaluation of multiple investigational medicinal products.
- Novel Drug Assessment
- Safety and Tolerability Studies
- Dose Optimization Research
Their work involves careful assessment of various therapeutic compounds and their effects on disease progression.
Clinical Monitoring
Expertise in conducting long-term safety and efficacy evaluations of experimental treatments for neuromuscular conditions.
- Treatment Safety Monitoring
- Therapeutic Response Assessment
- Patient Outcome Evaluation
The investigator's work includes comprehensive monitoring of treatment effects and patient responses over extended periods.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.